Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

In the past week, Wolfe Research upgraded Vertex Pharmaceuticals from “Peer Perform” to “Outperform,” citing growing ...

The company in 2026 is seeking approval from global regulators for Casgevy and two cystic fibrosis drugs in younger patients.

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

Europe’s health regulator followed the United States and the United Kingdom in backing the first gene-editing therapy to use Crispr technology, a Vertex Pharmaceuticals Inc. and Crispr Therapeutics AG ...

Vertex's comprehensive approach has already shaped the treatment of CF and earned it a dominant position worldwide. The chronic nature of therapy and limited competition on the horizon heighten the CF ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best ...

A U.S. flag flies next to the headquarters of Vertex in Boston (Reuters) -Vertex Pharmaceuticals sued the U.S. Department of Health and Human Services on Monday, seeking a court declaration that a ...

Vertex Pharmaceuticals (NASDAQ:VRTX) announced Tuesday that the U.S. FDA approved its groundbreaking gene editing therapy, Casgevy, developed with CRISPR Therapeutics (NASDAQ:CRSP) for those aged 12 ...

Casgevy, the first drug approved in the United States to use the revolutionary gene-editing tool called CRISPR-Cas9, was cleared by regulators on Tuesday to treat a second rare blood disorder. About ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Vertex Pharmaceuticals Inc. will ...

Europe’s health regulator followed the US and UK in backing the first gene-editing therapy to use Crispr technology, a Vertex Pharmaceuticals Inc. and Crispr Therapeutics AG treatment for sickle cell ...